Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2018

01-02-2018 | Original Article

Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

Authors: Margarita Kirienko, Luca Cozzi, Lidija Antunovic, Lisa Lozza, Antonella Fogliata, Emanuele Voulaz, Alexia Rossi, Arturo Chiti, Martina Sollini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2018

Login to get access

Abstract

Purpose

Radiomic features derived from the texture analysis of different imaging modalities e show promise in lesion characterisation, response prediction, and prognostication in lung cancer patients. The present study aimed to identify an images-based radiomic signature capable of predicting disease-free survival (DFS) in non-small cell lung cancer (NSCLC) patients undergoing surgery.

Methods

A cohort of 295 patients was selected. Clinical parameters (age, sex, histological type, tumour grade, and stage) were recorded for all patients. The endpoint of this study was DFS. Both computed tomography (CT) and fluorodeoxyglucose positron emission tomography (PET) images generated from the PET/CT scanner were analysed. Textural features were calculated using the LifeX package. Statistical analysis was performed using the R platform. The datasets were separated into two cohorts by random selection to perform training and validation of the statistical models. Predictors were fed into a multivariate Cox proportional hazard regression model and the receiver operating characteristic (ROC) curve as well as the corresponding area under the curve (AUC) were computed for each model built.

Results

The Cox models that included radiomic features for the CT, the PET, and the PET+CT images resulted in an AUC of 0.75 (95%CI: 0.65–0.85), 0.68 (95%CI: 0.57–0.80), and 0.68 (95%CI: 0.58–0.74), respectively. The addition of clinical predictors to the Cox models resulted in an AUC of 0.61 (95%CI: 0.51–0.69), 0.64 (95%CI: 0.53–0.75), and 0.65 (95%CI: 0.50–0.72) for the CT, the PET, and the PET+CT images, respectively.

Conclusions

A radiomic signature, for either CT, PET, or PET/CT images, has been identified and validated for the prediction of disease-free survival in patients with non-small cell lung cancer treated by surgery.
Appendix
Available only for authorised users
Literature
1.
2.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentral
3.
Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25:1462–74.CrossRefPubMed
4.
Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100:1891–5.CrossRefPubMedPubMedCentral
5.
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.CrossRefPubMed
6.
Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med. 2008;177:516–23.CrossRefPubMed
7.
Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.CrossRefPubMedPubMedCentral
8.
Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 2017;7:358.
9.
Bashir U, Siddique MM, Mclean E, Goh V, Cook GJ. Imaging heterogeneity in lung cancer: techniques, applications, and challenges. Am J Roentgenol. 2016;207:534–43.CrossRef
10.
Chalkidou A, O’Doherty MJ, Marsden PK. False discovery rates in PET and CT studies with texture features: a systematic review. PLoS One. 2015;10:1–18.CrossRef
11.
Rami-Porta R, Crowley J, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:4–9.PubMed
12.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328–54.CrossRefPubMedPubMedCentral
13.
Orlhac F, Nioche C, Buvat I. Technical Appendix — Local Image Features Extraction — — LIFEx —. 2016.
14.
Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: where do we stand? J Nucl Med. 2015;56:1642–4.CrossRefPubMed
15.
16.
Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KMW, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:1–17.CrossRef
17.
Velez-Cubian FO, Rodriguez KL, Thau MR, Moodie CC, Garrett JR, Fontaine JP, et al. Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases. J Thorac Dis. 2016;8:2454–63.CrossRefPubMedPubMedCentral
18.
Korasidis S, Menna C, Andreetti C, Maurizi G, D’Andrilli A, Ciccone AM, et al. Lymph node dissection after pulmonary resection for lung cancer: a mini review. Ann Transl Med. 2016;4:368.CrossRefPubMedPubMedCentral
19.
Brundage MD. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.
20.
21.
Kim D-H, Jung J, Son SH, Kim C-Y, Hong CM, Oh J-R, et al. Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non–small cell lung cancer. Clin Nucl Med. 2015;40:708–14.CrossRefPubMed
22.
Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014;55:1235–41.CrossRefPubMed
23.
Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014;14:896.CrossRefPubMedPubMedCentral
24.
Desseroit M-C, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging. 2016;43:1477–85.CrossRefPubMedPubMedCentral
25.
Larue RTHM, Defraene G, De Ruysscher D, Lambin P, Van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665.CrossRefPubMedPubMedCentral
26.
Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.PubMedPubMedCentral
27.
Coroller T, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RT, Hermann G, et al. CT-based radiomic signature predicts distant metastasis in lung. Radiother Oncol. 2015;114:345–50.CrossRefPubMedPubMedCentral
28.
Yuan M, Zhang Y-D, Pu X-H, Zhong Y, Li H, Wu J-F, et al. Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival. Eur Radiol. 2017;In press.
29.
Parmar C, Leijenaar RT, Grossmann P, Rios-Velazquez E, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep. 2015;5:11044.CrossRefPubMedPubMedCentral
30.
van Timmeren JE, Leijenaar RTH, van Elmpt W, Reymen B, Oberije C, Monshouwer R, et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiother Oncol. 2017;123:363–9.CrossRefPubMed
31.
Huynh E, Coroller TP, Narayan V, Agrawal V, Hou Y, Romano J, et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. Int J Radiat. 2016;120:258–66.
32.
Li Q, Kim J, Balagurunathan Y, Liu Y, Latifi K, Stringfield O, et al. Imaging features from pre-treatment CT scans are associated with clinical outcomes in non-small-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys. 2017;44:4341–9.
33.
Van Velden FHP, Kramer GM, Frings V, Nissen IA, Mulder ER, De Langen AJ, et al. Repeatability of radiomic features in non-small-cell lung cancer [(18F)]FDG-PET/CT studies: impact of reconstruction and delineation. Mol Imaging Biol. 2016;18:788–95.
34.
Yan J, Chu-shern JL, Loi HY, Khor LK, Sinha AK, Quek ST, et al. Impact of image reconstruction settings on texture features in 18 F-FDG PET. J Nucl Med. 2015;56:1667–74.CrossRefPubMed
Metadata
Title
Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery
Authors
Margarita Kirienko
Luca Cozzi
Lidija Antunovic
Lisa Lozza
Antonella Fogliata
Emanuele Voulaz
Alexia Rossi
Arturo Chiti
Martina Sollini
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3837-7

Other articles of this Issue 2/2018

European Journal of Nuclear Medicine and Molecular Imaging 2/2018 Go to the issue

Original Article

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

Original Article

A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer

Letter to the Editor

On the 18F–fluoride PET imaging quantification to predict 223Ra-dichloride treatment response

Correction

Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Original Article

Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer

Book Review

Klaus Bohndorf, Mark Anderson, Mark Davies, Herwig Imhof, Klaus Woertler: Imaging of bones and joints. A concise, multimodality approach